Literature DB >> 1924661

Premenstrual and menstrual symptom clusters and response to calcium treatment.

J M Alvir1, S Thys-Jacobs.   

Abstract

Fourteen perimenstrual symptoms were rated daily by 33 women in a randomized, double-blind, crossover trial of calcium supplementation. Factor analysis was performed on these symptoms using 2,413 daily ratings during the luteal and menstrual phases with at least one symptom present. Four factors (negative affect, water retention, food, and pain) accounting for 67 percent of the total variance were extracted. Internal consistency was high for scales based on these factors. Correlations between the scores ranged from .35 to .69. Scores were low during the intermenstrual phase and much higher during both luteal and menstrual phases. Paired t-tests comparing the intermenstrual phase with both luteal and menstrual phases all resulted in significant differences at p less than .01. There was more pain reported during the menstrual compared with the luteal phase (p less than .01). Calcium supplementation reduced negative affect (p = .045), water retention (p = .003), and pain (p = .036) during the luteal phase and pain (p = .02) during the menstrual phase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1924661

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  3 in total

Review 1.  Premenstrual syndrome. Identification and management.

Authors:  S K Severino; M L Moline
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

2.  Premenstrual dysphoric symptoms amongst Brazilian college students: factor structure and methodological appraisal.

Authors:  Chei-Tung Teng; Antônio Helio Guerra Vieira Filho; Rinaldo Artes; Clarice Gorenstein; Laura H Andrade; Yuan-Pang Wang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

3.  Differences in free estradiol and sex hormone-binding globulin in women with and without premenstrual dysphoric disorder.

Authors:  Susan Thys-Jacobs; Don McMahon; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2007-10-23       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.